Max Healthcare Institute Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Muted margin quarter, structural not operational: Network operating EBITDA margin fell to 24.8% from 26.8% QoQ, driven by newly commissioned brownfield beds and the Kalinga acquisition, not by deterioration in mature hospitals.
• Oncology mix shift distorts optics: Oncology fell to 22% of IP revenues from 26% YoY after Max stopped supplying select high-value chemo drugs to institutional patients; excluding oncology, gross revenue grew 20% and ARPOB grew 9%.
• New beds are ramping on schedule: Max Smart and Nanavati Phase 1 commissioned beds are both running at ~80% occupancy, with revenue and EBITDA now catching up to occupancy.
• Medical education is a new growth vector: Board approved entry into medical colleges after NMC rule change; management sees 25%+ ROCE and plans to start at Lucknow, then scale across campuses.
• What to watch next quarter: Whether oncology normalizes from Q3 as guided, the pace of CGHS collections recovery, and whether Nanavati EBITDA catches up to the corporate average with Phase 1 alone.

Margin Walk & Cost Structure

• The 200 bps QoQ margin dip: Recent commissioning of brownfield capacities at Mohali, Nanavati and Max Smart, plus the Kalinga acquisition, loaded indirect costs before revenues fully ramp.
• Direct cost pressure is clinician-led: Direct costs grew 16% vs revenue growth of 15%; the 1% excess is clinician costs, not consumables or crude, and management says these normalize as revenues ramp up.
• Indirect costs are the bigger swing: Large increase in indirect costs came from operationalizing new capacities at Mohali, Nanavati, Smart and Bhubaneswar.
• Opex trajectory is now flat: No material increase in opex expected until Gurugram comes up; revenue increases should drive higher EBITDA flow-through from here.
• New bed EBITDA trajectory is a known playbook: Occupancy ramps first, then revenue, then EBITDA; revenue ramp-up lags occupancy, EBITDA ramp-up lags revenue initially, then EBITDA ramp-up overtakes revenue ramp-up.

Soi: "First revenues, and then the profitability starts to flow in. So first, the occupancy will be high, revenue ramp up will be lower relatively and EBITDA ramp up will be lower even more so relatively. Then the second thing that starts happening, your revenue ramp up moves beyond your occupancy ramp up and your EBITDA starts picking up and then your EBITDA ramp up is going to overtake your revenue ramp up as well."

Oncology & Institutional Mix

• The oncology reset: Max stopped supplying ORC drugs for institutional patients from mid-Q3 FY26 after the new MOU was signed in October 2025; normalization is expected from Q3 FY27 onwards, fully normalized from Q4.
• Why Max felt it more than peers: Max had the largest oncology franchise at 25%+ of revenues, the highest institutional business, and the largest CGHS share due to Delhi presence.
• Institutional share is being deliberately reduced: Institutional share came down this quarter as a result of concerted effort, and management says the trend will continue with present infrastructure.
• Institutional business is structurally unprofitable: It has never been profitable, is loss-making, but contributes to fixed costs.
• CGHS super-specialty rates are now flowing: Left-out super-specialty rates started from June onwards; CGHS is on track for ₹140 crore for the year at ~₹35 crore/quarter run rate.

Soi: "The institutional business has never been profitable. It contributes to fixed costs... it is a loss-making business, but it contributes to fixed costs."

New Capacity & Ramp-Up

• Nanavati margin catch-up: Historically lower margins due to bed limitations and patient mix; EBITDA already ramping with Phase 1 and expected to catch up with corporate average with Phase 1 itself, not waiting for Phase 2.
• Bhubaneswar headroom: Management expects 50% to 80% enhancement in both occupancy and ARPOB from current 50% occupancy and ₹35,000 ARPOB; will also build another 200 to 250 beds alongside.
• Acquired hospitals are working: Lucknow, Noida and Nagpur all saw very high ramp-up in occupancy, revenues and profitability since acquisition; all three now moving to brownfield expansion.

Medical Education Entry

• The regulatory unlock: Draft NMC notification now allows for-profit companies to open medical colleges; restrictions on charges, ward requirements and infrastructure limitations have been removed.
• The plan: Start a medical college at the 27-acre Lucknow campus first, then potentially at other hospitals with large land parcels; intends to enter "at scale" and also start postgraduate courses.
• The economics: Around ₹300 crore capex for a 150-seat medical college; ROCEs of more than 25% to 30% seen at present; funded entirely through internal accruals.
• The demand backdrop: Less than 2% of students who qualify for NEET find places in medical colleges; management sees this as government impetus to increase seats.
• Timing is deliberately open: Commercial operations expected "over the next few years"; management is open to a meaningful acquisition to kick-start sooner.

Soi: "We are seeing ROCEs of more than 25%. I mean, you have been following the recent NEET incident, you are aware that less than 2% of students who qualify for NEET exams find places in medical colleges. I think this is the Government's impetus to increase seats in medical colleges."

Cash Flow & Balance Sheet

• Free cash flow lagged EBITDA: Operating free cash flow grew only 3% vs EBITDA growth of 15% because of AR movement; DSO rose from 87 to 95 days with ~₹250 crore AR build-up in Q1 vs Q4, driven by lumpiness in CGHS/PSU collections.
• CGHS portal was the bottleneck: The new CGHS portal was not processing bills; collections from the new portal have now started, and free cash flow is expected to normalize going forward.
• Net debt increase includes two items: ₹153 crore towards Kalinga and the put option liability for the balance stake in Yerawada (Pune project).
• Net debt trajectory: Barring acquisitions, net debt may marginally go up by end of year due to ongoing capex; over three to four years, capex should be funded and debt paid down.
• Acquisition headroom: Management willing to go up to 2.5x net debt-to-EBITDA for acquisitions.

Policy, Pricing & Long-Term View

• Parliamentary Committee report: Management sees no need to reassess expansion plans; any rational policy must cater to the mean, and Max is an outlier on efficiency.
• Insurance renewals: Ongoing negotiations with GIPSA and other insurers; previously agreed 6% automatic price revision applies at renewal in September-October; engagement with IRDAI for automatic inflation-linked increases continues.
• ARPOB growth is structural: Management expects ARPOB growth to remain superior to inflation over the next 10–15 years because real growth from novel treatments and technology is embedded in ARPOB, not just inflation.
• Capacity doubling ambition: Management sees capacity doubling every four to five years continuing for the next 15–20 years; illustrative path from 5,000 to 40,000 beds "at best"; no specific plans, "crystal ball gazing."
• On consolidation: Management does not see any player becoming 10x in two decades.

Soi: "Eventually, any policy has to cater to the mean, not to the outliers. And I believe as far as efficiency is concerned; we are outliers."

Guidance & Commitments

Key Metrics